NO20052362L - Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner - Google Patents

Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner

Info

Publication number
NO20052362L
NO20052362L NO20052362A NO20052362A NO20052362L NO 20052362 L NO20052362 L NO 20052362L NO 20052362 A NO20052362 A NO 20052362A NO 20052362 A NO20052362 A NO 20052362A NO 20052362 L NO20052362 L NO 20052362L
Authority
NO
Norway
Prior art keywords
dalbavancin
methods
treatment
bacterial infections
administering
Prior art date
Application number
NO20052362A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052362D0 (no
Inventor
Adriano Malabarba
Marco Cavaleri
Giorgio Mosconi
Daniela Jabes
Martin Stogniew
Timothy Henkel
Richard J White
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32330046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052362(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of NO20052362D0 publication Critical patent/NO20052362D0/no
Publication of NO20052362L publication Critical patent/NO20052362L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20052362A 2002-11-18 2005-05-12 Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner NO20052362L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42765402P 2002-11-18 2002-11-18
US48569403P 2003-07-08 2003-07-08
US49504803P 2003-08-13 2003-08-13
US49648303P 2003-08-19 2003-08-19
PCT/US2003/036127 WO2004045636A1 (en) 2002-11-18 2003-11-14 Methods of administering dalbavancin for treatment of bacterial infections

Publications (2)

Publication Number Publication Date
NO20052362D0 NO20052362D0 (no) 2005-05-12
NO20052362L true NO20052362L (no) 2005-08-17

Family

ID=32330046

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052362A NO20052362L (no) 2002-11-18 2005-05-12 Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner

Country Status (14)

Country Link
US (12) US6900175B2 (enExample)
EP (1) EP1565201B1 (enExample)
JP (3) JP5519090B2 (enExample)
KR (2) KR20120056310A (enExample)
AU (3) AU2003298662A1 (enExample)
CA (1) CA2506236C (enExample)
DK (1) DK1565201T3 (enExample)
ES (1) ES2712656T3 (enExample)
HU (1) HUE041133T2 (enExample)
IL (3) IL168327A (enExample)
MX (1) MXPA05005338A (enExample)
NO (1) NO20052362L (enExample)
PT (1) PT1565201T (enExample)
WO (3) WO2004045636A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO345529B1 (no) * 2004-04-27 2021-03-29 Vicuron Pharm Inc Dalbavancin-materialer for behandling av bakterielle infeksjoner

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298662A1 (en) 2002-11-18 2004-06-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20090062182A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched dalbavancin
US8389583B2 (en) * 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
US20110132607A1 (en) * 2009-12-07 2011-06-09 Schlumberger Technology Corporation Apparatus and Technique to Communicate With a Tubing-Conveyed Perforating Gun
WO2014152332A1 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
WO2015095658A1 (en) 2013-12-19 2015-06-25 Ge Healthcare Bio-Sciences Ab Remotely actuated valve for a biological liquid treatment system
BR112017000898A2 (pt) * 2014-07-17 2017-11-21 The Medicines Co oritavancina de alta pureza e método de produção da mesma
KR102763211B1 (ko) 2014-11-06 2025-02-04 셀리아 파마슈티칼즈 에이피에스 글리코펩티드 조성물
HK1247283A1 (zh) * 2015-03-02 2018-09-21 科罗纳里康赛普茨有限责任公司 用於peg代谢物及peg分解产物检测的化合物及方法
EP3294900B1 (en) 2015-05-08 2021-09-22 Spectral Platforms, Inc. Use of albumin-based non-covalent complexes for the detection of micro-organisms
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
JP7134995B2 (ja) 2017-03-20 2022-09-12 スペクトラル プラットフォームス インコーポレイテッド 微生物を検出し特徴づけるための分光法
EP3651739A4 (en) * 2017-07-10 2021-04-07 Contrafect Corporation BLOOD COMPONENT POTENTIALIZATION OF LYTIC PROTEIN ANTIBACTERIAL ACTIVITY AND RELATED METHODS AND USES
CN110183519B (zh) * 2019-05-06 2023-04-11 大邦(湖南)生物制药有限公司 一种达巴万星关键中间体a40926的分离纯化方法
CN112480214B (zh) * 2020-12-14 2023-03-28 成都雅途生物技术有限公司 一种达巴万星关键中间体a40926的制备方法
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CA3204571A1 (en) 2021-01-11 2022-07-14 Vidar Bjornstad Synthesis process
CN115215926A (zh) * 2022-08-12 2022-10-21 丽珠集团福州福兴医药有限公司 达巴万星母核及其纯化方法、达巴万星及其合成方法
WO2024079223A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
UY40481A (es) * 2022-10-12 2024-04-30 Hikma Pharmaceuticals Usa Inc Composición líquida de dalbavancina
EP4431084A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
EP4431083A1 (en) 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
WO2025158262A1 (en) 2024-01-23 2025-07-31 Lupin Limited Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation
GB202405996D0 (en) * 2024-04-29 2024-06-12 Arecor Ltd Novel compositions

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573679A (en) * 1896-12-22 Apparatus for mowing hay
US541616A (en) * 1895-06-25 Elevator attachment
GB1496386A (en) * 1975-03-05 1977-12-30 Lepetit Spa Antibiotics
US4195079A (en) 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
FI73697C (fi) 1982-06-08 1987-11-09 Lepetit Spa Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2.
FR2548021B1 (fr) 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8415092D0 (en) * 1984-06-13 1984-07-18 Lepetit Spa Ester derivatives
GB8425685D0 (en) 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
GB8428619D0 (en) * 1984-11-13 1984-12-19 Lepetit Spa Derivatives of antibiotic l 17046
US4914187A (en) 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
GB8512795D0 (en) 1985-05-21 1985-06-26 Lepetit Spa Increasing ratio of components of teicoplanin a2 complex
GB8531846D0 (en) 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608809D0 (en) 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
GB8621911D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GB8621912D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
GB8715735D0 (en) * 1987-07-03 1987-08-12 Lepetit Spa De-mannosyl teicoplanin derivatives
US4882313A (en) * 1987-07-31 1989-11-21 Smithkline Beckman Corporation Carboxamide derivatives of glycopeptides
GB8726859D0 (en) 1987-11-17 1987-12-23 Lepetit Spa 22-dechlorotei-coplanins
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2628269B1 (fr) * 1988-03-04 1990-07-27 Sgs Thomson Microelectronics Dispositif de demarrage progressif d'une alimentation a decoupage
ATE134646T1 (de) 1988-12-27 1996-03-15 Lepetit Spa C63-amidderivate von 34-de(acetylglucosaminyl)-34-deoxy-teicoplanine
IE64155B1 (en) 1989-03-29 1995-07-12 Lepetit Spa New substituted alkylamide derivatives of teicoplanin
JPH03193735A (ja) * 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
US5030619A (en) * 1990-04-16 1991-07-09 Miles Inc. Synergistic fungicidal composition
US5606036A (en) 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
AU666862B2 (en) 1991-07-29 1996-02-29 Vicuron Pharmaceuticals Inc. Amide derivatives of antibiotic A 40926
US6384013B1 (en) 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5882900A (en) 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CA2112776C (en) * 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
WO1994025588A2 (en) * 1993-04-30 1994-11-10 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
SI9500039B (sl) * 1995-02-07 2002-02-28 Lek, Nov kombiniran postopek čiščenja Vankomicin hidroklorida
EP0808326B1 (en) 1995-02-07 2001-09-12 Biosearch Italia S.p.A. Basic oxazoline-amide derivatives of ge 2270 and ge 2270-like antibiotics
SI0801655T1 (en) * 1995-02-07 1998-08-31 Biosearch Italia S.P.A. Basic proline-amide derivatives of ge 2270 and ge 2270-like antibiotics
US5789308A (en) * 1995-06-06 1998-08-04 Advanced Micro Devices, Inc. Manufacturing method for wafer slice starting material to optimize extrinsic gettering during semiconductor fabrication
CA2180206A1 (en) * 1995-06-30 1996-12-31 Motoya Ohshika Freeze-dried preparation for pharmaceutical use
AU701463B2 (en) * 1995-07-05 1999-01-28 Sanofi Aventis S.P.A. Purification of dalbaheptide antibiotics by isoelectric focusing
DE19600590A1 (de) * 1996-01-10 1997-07-24 Tzn Forschung & Entwicklung Schutzvorrichtung für optische Systeme zur Vermeidung von Schäden bei Bestrahlung dieser Systeme mit Laserlicht
DK0880541T3 (da) * 1996-02-14 2003-05-05 Biosearch Italia Spa Derivater af antibiotikum GE2270-faktorer
AU2441697A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Covalently-linked glycopeptide dimers
ATE208791T1 (de) * 1996-04-23 2001-11-15 Biosearch Italia Spa Chemisches verfahren zur herstellung von amidderivaten von a 40926 antibiotikum
US5935238A (en) * 1997-06-19 1999-08-10 Sun Microsystems, Inc. Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles
JP4204655B2 (ja) * 1997-08-08 2009-01-07 株式会社ルネサステクノロジ パルス出力機能付マイクロコンピュータ
CA2255140A1 (en) 1997-12-23 1999-06-23 Eli Lilly And Company Echinocandin binding domain of 1,3-.beta.-glucan synthase
US6541616B1 (en) * 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
US6417180B1 (en) 1998-10-07 2002-07-09 University Of Massachusetts Zinc finger-reactive antimicrobial compounds
ES2201825T3 (es) * 1998-12-23 2004-03-16 Theravance, Inc. Derivados del glicopeptidos y composiciones farmaceuticas que los contienen.
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
AU2001259298A1 (en) 2000-05-02 2001-11-12 Advanced Medicine, Inc. Polyacid glycopeptide derivatives
AU2003229475A1 (en) 2002-02-18 2003-09-09 Combinature Biopharm Ag Novel glycopeptide antibiotics and method for synthesis thereof
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
AU2003298662A1 (en) 2002-11-18 2004-06-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO345529B1 (no) * 2004-04-27 2021-03-29 Vicuron Pharm Inc Dalbavancin-materialer for behandling av bakterielle infeksjoner

Also Published As

Publication number Publication date
US20090305953A1 (en) 2009-12-10
US20090298748A1 (en) 2009-12-03
WO2004046196A3 (en) 2004-08-19
JP5519090B2 (ja) 2014-06-11
EP1565201B1 (en) 2018-10-31
DK1565201T3 (en) 2019-02-25
US20040198715A1 (en) 2004-10-07
CA2506236C (en) 2018-07-17
AU2003294262B2 (en) 2007-08-23
EP1565201A1 (en) 2005-08-24
CA2506236A1 (en) 2004-06-03
US7115564B2 (en) 2006-10-03
WO2004046196A2 (en) 2004-06-03
US20050090433A1 (en) 2005-04-28
JP2013155188A (ja) 2013-08-15
KR101173310B1 (ko) 2012-08-10
HUE041133T2 (hu) 2019-05-28
HK1114014A1 (en) 2008-10-24
ES2712656T3 (es) 2019-05-14
US20050032721A1 (en) 2005-02-10
KR20120056310A (ko) 2012-06-01
KR20050094396A (ko) 2005-09-27
IL230875A0 (en) 2014-03-31
US20050004011A1 (en) 2005-01-06
US20040224908A1 (en) 2004-11-11
US20050130909A1 (en) 2005-06-16
AU2003298662A1 (en) 2004-06-15
HK1083684A1 (en) 2006-07-07
IL168327A (en) 2014-02-27
NO20052362D0 (no) 2005-05-12
AU2003294262A1 (en) 2004-06-15
US20040197415A1 (en) 2004-10-07
MXPA05005338A (es) 2005-12-14
US6900175B2 (en) 2005-05-31
US20040220122A1 (en) 2004-11-04
US20040142883A1 (en) 2004-07-22
JP2006514092A (ja) 2006-04-27
JP2011157381A (ja) 2011-08-18
WO2004045637A1 (en) 2004-06-03
IL239913B (en) 2019-01-31
PT1565201T (pt) 2019-02-05
AU2003299561A1 (en) 2004-06-15
WO2004045636A1 (en) 2004-06-03
IL239913A0 (en) 2015-08-31
US20050130914A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
NO20052362L (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
MXPA05006670A (es) Administracion de capsaicinoides.
WO1999008691A8 (en) Use of locally delivered metal ions for treatment of periodontal disease
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
WO2002078627A3 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
NO20090887L (no) Fremgangsmate for behandling og forebygging av mukositt
BR0210075A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
EP1620061A4 (en) ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRES
TW200719903A (en) Compositions for the treatment of neoplasms
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
MX2025009380A (es) Polipéptido y sus derivados, composición que comprende los mismos, y uso de los mismos
MXPA02007641A (es) Uso de farmaceutico de la combinacion de fluconazol-tinidazol y su composicion para la administracion oral.
NO20073635L (no) Kombinasjonsbehandling for multippel sklerose
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application